Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 5/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5223463 | 1.00 | OPRD1 (0.41) | OPRD1OPRK1OPRM1ABCB1SLC6A2 | |
| SCHEMBL5224985 | 0.87 | OPRM1 (0.39) | OPRD1OPRK1OPRM1ABCB1BCHE | |
| SCHEMBL5224996 | 0.87 | OPRM1 (0.39) | OPRD1OPRK1OPRM1ABCB1BCHE | |
| SCHEMBL5930323 | 0.87 | SLC6A2 (0.43) | SLC6A2SLC6A4RIPK1 | |
| SCHEMBL5930327 | 0.87 | SLC6A2 (0.43) | SLC6A2SLC6A4RIPK1 | |
| SCHEMBL609658 | 0.86 | ANPEP (0.42) | OPRD1OPRK1OPRM1ABCB1BCHE | |
| SCHEMBL609656 | 0.86 | ANPEP (0.42) | OPRD1OPRK1OPRM1ABCB1BCHE | |
| SCHEMBL4869209 | 0.85 | ABCB1 (0.39) | OPRD1OPRK1OPRM1ABCB1BCHE | |
| SCHEMBL4869199 | 0.85 | ABCB1 (0.39) | OPRD1OPRK1OPRM1ABCB1BCHE | |
| SCHEMBL5223492 | 0.85 | OPRM1 (0.40) | OPRD1OPRK1OPRM1ABCB1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20060229302-A1 | Tricyclic indole derivatives and their use in the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229302-A1 | Tricyclic indole derivatives and their use in the treatment of alzheimer's disease | BACE2, BACE1, PSEN2 | OPRD1 505/4885OPRK1 437/4885OPRM1 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.